Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

THOUSAND OAKS, Calif., Oct. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that effective Dec. 31, 2019, Repatha® (evolocumab), an innovative treatment for patients with high ...

Amgen's cholesterol-lowering antibody Repatha is being launched in Europe at well below the new drug's cost in the US, raising the chance that American payers will seek hefty discounts on the drug.

A federal jury in Delaware said on Thursday that biotech company Amgen owes competitor Regeneron more than $406 million for ...

THOUSAND OAKS, Calif., Nov. 16, 2019 /PRNewswire/ -- Amgen today announced a new analysis from the Repatha® (evolocumab) cardiovascular outcomes ( ...

Three Motley Fool contributors believe they've found no-brainer healthcare stocks to buy in June. (Amgen): One of the best ...

The drugmaker said Repatha would start with a list price of $14,100 for a year’s worth of treatment. Developed by Amgen’s scientists, it is the second in a new class of drugs that lower ...

Amgen’s Repatha and Sanofi/Regeneron’s Praluent are competing for market share in the new class of PCSK9 inhibitors for high-risk cholesterol patients after both were approved by FDA this summer.

With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, ...

If you are pregnant or are breastfeeding while taking Repatha, you can take part in an ongoing safety study by calling 800-77-AMGEN (800-772-6436). Reports of side effects are very important and ...

Commercializing Amgen's recently approved cholestserol fighter Repatha across the EU hit a road block this week when cost crunchers in the U.K. determined that the drug didn't deliver the right ...

Federal Circuit invalidated patents on blockbuster Amgen cholesterol drug U.S. Solicitor General says decision was reasonable (Reuters) - The Biden Administration told the U.S. Supreme Court on ...